RNTX
Rein Therapeutics, Inc.Company with tickers: RNTX
CIK
1420565
CUSIP
00887A204
Shares Outstanding
85,539,032
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $0 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $5,230,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Research & Development | $3,073,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Operating Income | $-5,230,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| Net Income | $-5,838,000 | USD | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Basic) | $-0.19 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |
| EPS (Diluted) | $-0.19 | USD/shares | 2026-03-31 | 10-Q | 2026-05-15 |